财联社1月8日电,创新药概念延续强势,必贝特20cm涨停,走出2连板,华人健康、悦康药业、泓博医药、奥锐特、百诚医药跟涨。消息面上,国家药监局进一步优化这类药品审评审批。鼓励临床急需境外已上市的原研药及仿制药在境内申报。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.